Synonyms: | |
Status: | Approved (1985) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N06AX12 |
UNII: | 01ZG3TPX31 |
InChI Key | SNPPWIUOZRMYNY-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C13H18ClNO |
Molecular Weight | 239.75 |
AlogP | 3.3 |
Hydrogen Bond Acceptor | 2.0 |
Hydrogen Bond Donor | 1.0 |
Number of Rotational Bond | 3.0 |
Polar Surface Area | 29.1 |
Molecular species | NEUTRAL |
Aromatic Rings | 1.0 |
Heavy Atoms | 16.0 |
Primary Target | |
---|---|
DAT | |
NET |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor alpha subunit
|
- | 12-12000 | - | - | - | |
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor beta subunit
|
- | 12-12000 | - | - | - | |
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor delta subunit
|
- | 8-7900 | - | - | - | |
Ion channel
Ligand-gated ion channel
Nicotinic acetylcholine receptor
Nicotinic acetylcholine receptor gamma subunit
|
- | 8-7900 | - | - | - | |
Membrane receptor
|
- | 1800 | - | - | - | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC06 neurotransmitter transporter family
|
- | 550-2900 | - | 441-871 | 62 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 7-109 |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Depressive Disorder | 4 | D003866 | ClinicalTrials |
Depressive Disorder | 4 | D003866 | ClinicalTrials |
Anxiety | 3 | D001007 | ClinicalTrials |
Dementia | 3 | D003704 | ClinicalTrials |
Depressive Disorder, Major | 3 | D003865 | ClinicalTrials |
Schizophrenia | 3 | D012559 | ClinicalTrials |
Tobacco Use Disorder | 3 | D014029 | ClinicalTrials |
Attention Deficit Disorder with Hyperactivity | 3 | D001289 | ClinicalTrials |
Smoking Cessation | 3 | D016540 | ClinicalTrials |
Obesity | 3 | D009765 | ClinicalTrials |
Huntington Disease | 2 | D006816 | ClinicalTrials |
Crohn Disease | 2 | D003424 | ClinicalTrials |
Amphetamine-Related Disorders | 2 | D019969 | ClinicalTrials |
Marijuana Abuse | 2 | D002189 | ClinicalTrials |
Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
Alcoholism | 2 | D000437 | ClinicalTrials |
Cocaine-Related Disorders | 2 | D019970 | ClinicalTrials |
Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
Restless Legs Syndrome | 2 | D012148 | ClinicalTrials |
Mitochondrial Diseases | 1 | D028361 | ClinicalTrials |
Alzheimer Disease | 1 | D000544 | ClinicalTrials |
Bipolar Disorder | 1 | D001714 | ClinicalTrials |
Neoplasms | 1 | D009369 | ClinicalTrials |
Diabetes Mellitus, Type 2 | 1 | D003924 | ClinicalTrials |
Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
Sexual Dysfunction, Physiological | 1 | D012735 | ClinicalTrials |
Head and Neck Neoplasms | 1 | D006258 | ClinicalTrials |
Melanoma | 1 | D008545 | ClinicalTrials |
Prostatic Neoplasms, Castration-Resistant | 1 | D064129 | ClinicalTrials |
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | D015451 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 34911-55-2 |
ChEBI | 3219 |
ChEMBL | CHEMBL894 |
DrugBank | DB01156 |
DrugCentral | 435 |
EPA CompTox | DTXSID7022706 |
FDA SRS | 01ZG3TPX31 |
Human Metabolome Database | HMDB0001510 |
Guide to Pharmacology | 7135 |
KEGG | C06860 |
PharmGKB | PA448687 |
PubChem | 444 |
SureChEMBL | SCHEMBL38777 |